Preferred Label : Gefurulimab;
NCIt definition : A humanized bispecific VHH antibody directed against terminal complement protein C5
and albumin, with potential anti-inflammatory and immunomodulatory activities. Upon
administration, gefurulimab, with its anti-C5 antibody moiety, targets and binds to
terminal complement protein C5, thereby blocking the terminal complement pathway of
complement activation. This inhibits complement-mediated inflammation and cell lysis.
Excessive complement activation plays a key role in various inflammatory and autoimmune
diseases, and leads to tissue destruction. The binding of gefurulimab to albumin,
with its albumin binding domain, increases its half-life.;
UNII : 6PWU78BV6C;
CAS number : 2456407-94-4;
Molecule name : ALXN 1720; ALXN-1720;
NCI Metathesaurus CUI : CL1778574;
Origin ID : C186389;
UMLS CUI : C5670500;
Semantic type(s)
- concept_is_in_subset
- has_target
